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REDUCED TOXICITY CONDITIONING (RTC) AND ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT) FOR PEDIATRIC SICKLE CELL DISEASE
(SCD): SIGNIFICANT IMPROVEMENT IN PHYSICAL FUNCTIONING
Oberg, J.A.1, Sands, S.S.1, Bhatia, M.1, Morris, E.2, Cairo, M.S.2
1Columbia University, New York, NY; 2New York Medical College,
Valhalla, NY
Purpose: SCD is characterized by chronic organ dysfunction and
poor quality of life (QOL). Myeloablative conditioning (MAC) and
AlloSCT for SCD is the only curative therapy for children who are
at high risk for SCD related morbidity and mortality (Bhatia et al,
BMT, 2008).MAC and alloSCT are associated with significant acute
morbidity and late effects (Satwani/Cairo et al, BBMT 2005). De-
spite the emerging clinical benefit of RTC alloSCT in SCD
(Bhatia/Cairo et al, ASBMT, 2011), little is known about its impact
on the longitudinal QOL of these patients. Therefore, the objective
of this study was to serially evaluate the QOL of children who re-
ceived RTC alloSCT for SCD.
Methods: Hierarchical linear modeling was used to explore trends
in PedsQL 4.0 physical, emotional, and social functioning sub-scales
and select individual items of 14 children$ 5 years of age undergo-
ing alloSCT for SCD between 2004 and 2008 at Columbia Univer-
sity Medical Center. QOL was assessed once pre-alloSCT and days
100, 180, 365, and 730, post-alloSCT. Post hoc exploratory analyses
were performed to further evaluate the effect of RTC and alloSCT
on outcomes. Effect sizes (ES) were included to describe the magni-
tude of difference in scores from baseline.
Results:Mean age: 9.9 years. Emotional and social functioning was
stable over time. Physical functioning (PF) was estimated to im-
prove from baseline (BL) for parent (M 5 69.54) and child self-
report (M 5 72.96) at a rate of 0.57 (p 5 0.06) and 0.43 (p 5
0.16) points per month (ppm) respectively, with a large difference
estimated at 2-years post-alloSCT by parent report (ES 5 0.93
SD) and a moderate difference by child self-report (ES 5 0.70
SD). Post hoc analysis of parent reported PF items revealed statisti-
cally significant improvements from BL in running, pain, and fa-
tigue (Table 1). A large ES difference was estimated for each of
these items at 2-years post-alloSCT with running scoring 0.99 SD
higher, pain improving by 1.72 SD, and fatigue by 1.31 SD.
Children who received a matched related donor (MRD) transplant
(M 5 69.05) significantly improved at a rate of 0.93 ppm/11.31
points per year (ppy) (t 5 3.08; p 5 0.00), whereas children who
received a matched unrelated donor (MUD) alloSCT reported
a significant decline from BL (M 5 85.14) in PF of 2.57 ppm/
31.23 ppy (t 5 3.74; p 5 0.00).
Conclusion: RTC and alloSCT in poor risk SCD was associated
with significant improvements in physical functioning including run-
ning, pain and fatigue.
Table 1. Models for Physical Functioning Items by Rater
Parent ChildFixed Effect Coeff SD P Coeff SD PWalking
Intercept, b00 77.71 14.45 0.00 86.63 10.11 0.00
Time, b10 0.67 21.36 0.12 0.75 14.99 0.02
Running
Intercept, b00 71.21 21.89 0.00 70.02 27.04 0.00
Time, b10 0.91 22.28 0.05 0.50 25.07 0.34
Exercise
Intercept, b00 74.01 21.31 0.00 72.19 12.09 0.00
Time, b10 -0.27 20.29 0.52 0.25 26.95 0.64
Lifting
Intercept, b00 69.62 16.43 0.00 63.45 9.80 0.00
Time, b10 0.29 26.69 0.59 0.01 34.24 0.99
Hurt or Ache
Intercept, b00 53.47 24.03 0.00 81.07 24.78 0.00
Time, b10 1.11 15.69 0.00 0.53 24.60 0.30(Continued )Table 1. (Continued)Parent ChildFixed Effect Coeff SD P Coeff SDSPLow Energy
Intercept, b00 60.05 16.15 0.00 74.97 1.29 0.00
Time, b10 1.20 22.35 0.01 -0.29 36.01 0.67200
CHRONIC GVHD AND AGE ARE NOT ASSOCIATED WITH BONE MINERAL
DENSITY LOSS IN THE SECOND DECADE POST-ALLOGENEIC STEM CELL
TRANSPLANTATION
Pophali, P.A.1, Klotz, J.1, Koklanaris, E.1, Savani, B.N.2, Chawla, K.1,
Le, R.Q.1, Wu, C.1, Barrett, J.1, Battiwalla, M.1 1NHLBI, NIH,
Bethesda, MD; 2Vanderbilt University, Nashville, TN
Introduction: Accelerated bone mineral density loss (BMDL) oc-
curs early after allogeneic stem cell transplantation (SCT) but little
is known about the natural history of BMDL in the second decade
(2ndD) of survivorship.
Methods:We evaluated 134 recipients (77 males and 57 females) of
allogeneic SCT performed between 1993 and 2006, who survived
.3 years. Median age at transplant was 35 years. Transplant indica-
tions wereCML (61), acute leukemia (43),MDS (18) and others (12).
Patients received$12 GyTBI-based (120) or reduced intensity con-
ditioning (14) followed by marrow (15) or T cell depleted peripheral
blood SCT (119). Post-SCT, all patients received calcium/vitaminD
supplementation but not bisphosphonates. All women received hor-
mone replacement therapy. Forty-three of 111 patients having
chronic GVHD required systemic immunosuppressive therapy for
.3 years (IST.3). A subset of 42 survivors in their 2ndD (median
age 47 years) was identified.
Survivors were classified by lowest T-scores (WHO) as normal
($-1) or BMDL: osteopenia (\-1 and .-2.5) and osteoporosis
(#-2.5, Z-score\-2 for children). Test for trends used the linear
mixed model. Multivariable linear regression was performed for
the lowest T-scores and logistic regression for osteoporosis and
BMDL.
Results: BMDL occurred in 105 (78%) survivors: 64 (48%) osteo-
penic and 41 (31%) osteoporotic. Trend analysis showed a gradual
but significant improvement in T-scores over time. The rate of im-
provement was greater in younger survivors but was unaffected by
gender. In multivariable analyses, 4th quartile age (p 5 0.001) and
IST.3 (p 5 0.047) were significantly associated with the lowest
T-score. Age in the 4th quartile (odds ratio 3.4, p\0.01) and IST
.3 (odds ratio 2.3, p 5 0.05) also increased the risk of osteoporosis.
Primary diagnosis, conditioning regimen, stem cell source and gen-
der were not statistically significant.
Thirty-one (74%) 2ndD survivors continued to have BMDL: 16
(38%) osteopenic and 15 (36%) osteoporotic. Chronic GVHD and
age had no association with T-score, osteoporosis or BMDL in
this subset.
Conclusions: There is a high prevalence of BMDL in allogeneic
SCT survivors with a gradual trend towards improvement with
time, influenced by age but not gender. Age and IST.3 are signifi-
cantly associated with BMDL in the first decade. The loss of associ-
ation with age and prolonged IST in the 2ndD survivors implies that
other factors may account for persistent BMDL in the 2ndD.201
FLUDARABINE-BASED REDUCED-INTENSITY (RIC) OR REDUCED-
TOXICITY CONDITIONING (RTC) MAY BE ASSOCIATED WITH INCREASED
RISK FOR SECONDARY MALIGNANCIES AFTER ALLOGENEIC STEM-CELL
TRANSPLANTATION (SCT)
Shimoni, A., Shem-Tov, N., Tallis, E., Danylesko, I., Volchek, Y.,
Yerushalmi, R., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel
Secondary malignancies are a known complication in long-term
survivors following myeloablative conditioning (MAC), however277
S278 Poster Session Itheir incidence and risk-factors following fludarabine (F)-based
RIC and RTC has not been well defined, due to still limited fol-
low-up after these novel regimens. We retrospectively reviewed
data of 931 patients (pts) given allogeneic SCT over a 12 year pe-
riod to identify pts with secondary malignancies. Conditioning
regimens included standard MAC (n 5 257, TBI-based in 111),
F-based RIC [n 5 449, including F with intermediate-dose busul-
fan, (FB2), and F with melphalan (FM)] or F-based RTC
[n 5 225, including F with high-dose busulfan, (FB4), and F
with treosulfan (FT)]. 21 pts had secondary malignancies including
squamous cell carcinoma of the skin (n 5 5), penis (n 5 1) vagina
(n 5 1), tongue (n 5 1) and esophagus (n 5 2), colon cancer (n 5
3), breast cancer (n 5 2), pancreatic cancer (n 5 2), metastatic can-
cer of unknown primary (n 5 1), melanoma (n 5 1), metastatic
sarcoma (n 5 1), Kaposi sarcoma (n 5 1). In all, 5 pts had meta-
static or locally advanced solid tumor at presentation. The median
age at SCT was 53 years (29-70). 19 pts were given F-based RIC/
RTC and none had TBI. The median time from SCT to diagnosis
of second malignancy was 49 months (7 months-11.5 years). 17 pts
had prior cGVHD, 10 moderate-severe and 14 were still on im-
munosuppressive therapy at the diagnosis of secondary malig-
nancy. The 10-year cumulative incidence of secondary
malignancy was 5.3% (95%CI, 3.2-8.7%). It was 2.2% after
BuCy, 8.8% after FB2, 5.5% after FM, 7.8% after FB4 and
5.5% after FT (p 5 0.05 for BuCy Vs. RIC/RTC). Multivariate
analysis identified RIC/RTC and moderate-severe cGVHD as ad-
verse prognostic factors, HR 5.9 (p 5 0.03) and 2.7 (p 5 0.04), re-
spectively. Pts were treated with surgery for localized tumors and
with chemo-radiotherapy or palliative therapy for metastatic dis-
ease. Currently, 17 pts are alive and 4 died, all of them had ad-
vanced solid tumor at presentation. The cumulative incidence of
death due to secondary malignancy was 1.6% at 10 years after
SCT. In conclusion, secondary malignancies are rare but signifi-
cant complication after allogeneic SCT. Curative approach is fea-
sible in a subset of pts. The combination of F and intermediate to
high-dose alkylating agent may be associated with higher risk for
second malignancies than standard therapy with high-dose alkyla-
tors and/or TBI. Larger registry studies with more events are
needed to confirm these observations.202
LONG-TERM FOLLOW-UP OF HEMATOPOIETIC CELL TRANSPLANT (HCT)
RECIPIENTS AFTER RSV PNEUMONIA
Seo, S.1, Chien, J.W.2,3, Campbell, A.P.1,3,4, Reyes, D.L.3, Boeckh,M.1,2,3
1Fred Hutchinson Cancer Research Center, Seattle, WA; 2University of
Washington, Seattle, WA; 3Fred Hutchinson Cancer Research Center,
Seattle, WA; 4University of Washington, Seattle, WA
Background: Respiratory syncytial virus (RSV) infection can
cause severe pneumonia after HCT. Although there are many
reports about early clinical outcomes after RSV pneumonia,
late sequelae are less well characterized. Therefore, we investi-
gated the late pulmonary function effects of RSV pneumonia af-
ter HCT.
Patients andMethods:HCT recipients who had RSV pneumonia
(radiographic signs and BAL positive for RSV by PCR, DFA or
culture) between 1/1990 and 3/2010 and survived for at least 1
month were retrospectively reviewed. Patients who had pulmonary
function tests (PFTs) at the time of both pre- and post- (day
60625 and/or 1 year680 days) RSV pneumonia were analyzed.
Airflow obstruction was defined as FEV1/FVC\0.7,
FEV1#75%, and FEV1 decrease of $10% according to the mod-
ified NIH guidelines. All patients received aerosolized ribavirin
(RBV) +/- palivizumab.
Results: A total of 28 patients had RSV pneumonia a median of
29.5 days after HCT (range, 9- 1515 days) and survived for at least
1 month. Median patient age was 37 years (range, 10- 67); 27/28
were allograft recipients. Survival at 100 days and 1 year after
RSV pneumonia was 89.3% and 78.6%, respectively; all deaths
were unrelated to RSV (5 died of non-respiratory causes and one
with respiratory failure due to bronchiolitis obliterans). PFTs atday 60 showed significant decreases of %FEV1 and %DLCO com-
pared with before RSV pneumonia (29.5%613.0, p 5 0.003,
224.0%618.2, p\ 0.001, respectively). Pulmonary function at 1
year after RSV pneumonia was also significantly decreased when
compared to baseline (%FEV1: 26.9%612.0, p 5 0.049, %
DLCO: 216.7%621.2, p 5 0.01) but not significantly improved
compared with day 60 measurements. Seventeen patients received
palivizumab in addition to aerosolized RBV in a non-randomized
fashion (there were no significant differences in patient age, acute
and chronic GVHD, or pretransplant PFTs between patients
who did and did not receive palivizumab). Analysis stratified by
palivizumab use did not significantly affect the PFT observations.
Airflow obstruction at 1 year post RSV pneumonia was detected
in 4 of 16 patients. Palivizumab use did not affect the incidence
of airflow obstruction (20% with palivizumab and 33% without,
p 5 0.6).
Conclusions: Long term survivors of RSV pneumonia after HCT
may be at risk for persistent airflow abnormalities. The addition of
palivizumab did not appear to improve late pulmonary function in
this relatively small retrospective study.203
LATE MORTALITY AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTA-
TION FOR A CHILDHOOD MALIGNANCY
Scehchter, T.1, Pole, J.D.2, Darmawikarta, D.2, Doyle, J.1, Irwin, M.1,
Egeler, M.1, Ali, M.1, Gassas, A.1, Greenberg, M.2,1, Nathan, P.1 1The
Hospital for Sick Children, Toronto, ON, Canada; 2Pediatric Oncology
Group of Ontario, Toronto, ON, Canada
Hematopoietic stem cell transplantation (HSCT) is used in-
creasingly as a curative therapy in children with malignancies.
However, survivors of HSCT are at risk for disease recurrence
and life-threatening complications. The risk for late mortality
(.2 years) after autologous and allogeneic HSCT has not been
well reported in children. The aim of this population-based ret-
rospective cohort study was to assess late mortality in children
(age 0-18 y-o) who underwent a HSCT in the province of
Ontario, Canada. Nearly all of the province’s pediatric transplan-
tations are performed at a single center (SickKids). Indication for
HSCT, type of transplant, donor source and survival were deter-
mined via a record linkage between the SickKids’ transplant da-
tabase and POGONIS, the provincial pediatric cancer registry.
Mortality information contained in POGONIS is captured at
the time of death in hospital, or by record linkage to the provin-
cial mortality file. Records of all 756 children who were Ontario
residents with a malignancy and underwent HSCT at SickKids
between 1985-2009 were retrieved. Underlying diagnoses were
leukemia (N 5 412), lymphoma (N 5 82), CNS tumor (N 5
55), neuroblastoma (N 5 150), sarcoma (N 5 41) and other
(N 5 16). 372 children underwent allogeneic HSCT and 384 un-
derwent autologous HSCT. Among the allogeneic HSCT group,
226 (60.8%) received related donor HSCT. Overall, 479 children
(63.4%) survived for at least 2 years after HSCT. The median
follow-up of these 479 survivors was 9.98 years. Of these 479
survivors, 98 (20.5%) subsequently suffered a late death. A
greater proportion of patients who underwent autologous
HSCT had a late death (64/251; 25.5%) than patients post allo-
geneic HSCT (34/228; 14.9%). In a multivariate analysis of pa-
tients who underwent autologous HSCT, males had increased
risk of death compared to females (HR 5 2.0, 95% CI:1.12-
3.59), and patients treated for neuroblastoma had a greater risk
of death than those treated for leukemia (HR 5 10.0, 95%
CI:2.78-36.2). Among patients treated with allogeneic HSCT,
none of gender, donor source (related vs. unrelated), age at trans-
plant or underlying diagnosis was associated with increased late
mortality.
In conclusion, children with cancer who are treated with a HSCT
continue to be at risk for premature death even if they survive for 2 or
more years after their transplant. Further investigation will focus on
examining the contributions of treatment toxicity and disease recur-
rence to late mortality.
